OUR SCIENCE
Revolutionizing Cancer Immunotherapy
Discover how our advanced nanoparticle technology is transforming cancer treatment.
Saros is pioneering a new era in cancer immunotherapy with our advanced nanoparticle technology.
Our platform is designed to precisely target and enhance pathways of innate immune activation, starting with the STING pathway. This technology addresses the limitations of existing STING agonists by delivering a more effective and safer approach. Our nanoparticles are engineered to target not only tumor tissues but also critical immune cells such as macrophages and dendritic cells, ensuring comprehensive activation of the STING pathway where it is needed most.
Through extensive research and development, including comparative studies with other STING activating agents, we have demonstrated the superiority of our approach. Our biodistribution and toxicology studies confirm the safety profile of our technology, while multiple pre-clinical models provide robust support for its efficacy. At Saros, we are committed to maintaining the highest standards of scientific rigor and objectivity, as reflected in our financial conflict of interest policy. Our goal is to deliver groundbreaking immunotherapies that significantly improve patient outcomes and advance the field of cancer treatment.
Multiple pre-clinical models in mice, rabbits, and human cell lines support the efficacy and safety of our first agent.
Sun, X., Zhang, Y., Li, J. et al “Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy,” Nature Nanotechnology, 16, 1260-1270 (2021).
Sun, X., Zhou, X., Lei, Y., Moon, J., “Unlocking the promise of systemic STING agonist for cancer immunotherapy,” Journal of Controlled Release, 357, 417-421 (2023).
…
Saros promotes objectivity in its research. See our financial conflict of interest policy.
Get in Touch with Us.
Have questions or want to learn more about our innovative treatments? Reach out to our team—We welcome your collaboration to deliver improved cancer immunotherapy.